表紙:ペプチド治療薬の世界市場 (種類別、合成技術別、製造方法別、用途別、地域別):考察・予測、新型コロナウイルス感染症 (COVID-19) の潜在的な影響 (2022年~2026年)
市場調査レポート
商品コード
1092283

ペプチド治療薬の世界市場 (種類別、合成技術別、製造方法別、用途別、地域別):考察・予測、新型コロナウイルス感染症 (COVID-19) の潜在的な影響 (2022年~2026年)

Global Peptide Therapeutics Market (by Type, Synthesis Technology, Manufacturing Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 89 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.31円
ペプチド治療薬の世界市場 (種類別、合成技術別、製造方法別、用途別、地域別):考察・予測、新型コロナウイルス感染症 (COVID-19) の潜在的な影響 (2022年~2026年)
出版日: 2022年06月21日
発行: Koncept Analytics
ページ情報: 英文 89 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のペプチド治療薬の市場規模は、2022年から2026年にかけて6.95%のCAGRで成長し、2026年には444億3,000万米ドルに達すると予測されています。 市場の主な促進要因として、がんの有病率の急増や、医療費支出の増加、代謝障害の発生率の増加、高齢者人口の増加、ペプチドベース治療薬の承認件数の急増といった要因が挙げられます。他方、ジェネリック医薬品やバイオシミラー医薬品の入手可能性、医薬品開発費用の高さ、厳しい規制要件、ペプチドの生産の複雑さなどが市場の成長を阻害すると思われます。

地域別に見ると、北米市場が最も急速に成長すると見込まれています。

当レポートでは、世界のペプチド治療薬の市場について分析し、全体的な市場規模の動向見通しや、種類別・合成技術別・製造方法別・用途別および地域別・国別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルなどを調査しております。

目次

第1章 市場概要

  • イントロダクション
  • ペプチドの製造工程
  • ペプチドの分類
  • 治療用ペプチド・タンパク質の機能分類
  • ペプチドベース医薬品の例
  • 治療用ペプチドの長所と短所
  • 初期ペプチドの供給源または化学的性質

第2章 新型コロナウイルス感染症 (COVID-19) の影響

  • COVID-19関連の研究におけるペプチドの採用
  • 臨床試験の混乱

第3章 世界市場の分析

  • 世界のペプチド治療薬市場 (金額ベース)
  • 世界のペプチド治療薬市場、予測 (金額ベース)
  • 世界のペプチド治療薬市場:種類別
    • 革新的ペプチド治療薬
    • ジェネリックペプチド治療薬
  • 世界のペプチド治療薬市場:合成技術別
    • 固相ペプチド合成
    • 液相ペプチド合成
    • ハイブリッド技術
  • 世界のペプチド治療薬市場:製造方法別
    • 外部委託
    • 社内製造
  • 世界のペプチド治療薬市場:用途別
    • 代謝障害
    • 腫瘍
    • 胃腸障害
    • 心血管障害
    • 神経障害
  • 世界のペプチド治療薬市場:地域別

第4章 地域別の市場分析

  • 北米
    • ペプチド治療薬市場 (金額ベース)
    • ペプチド治療薬市場、予測 (金額ベース)
    • 米国市場の予測
    • 米国市場の予測:種類別
  • 欧州・中東・アフリカ
  • アジア太平洋
  • ラテンアメリカ

第5章 市場力学

  • 促進要因
    • がん有病率の急上昇
    • 医療費の増加
    • 代謝障害の発生率の上昇
    • 高齢者人口の増加
    • ペプチドベース治療薬の承認件数の急増
  • 主な傾向と動静
    • ジェネリック医薬品によづペプチド市場の量的拡大
    • ペプチドAPIの外注生産の急速な普及
    • 新薬の研究開発への投資の増加
  • 課題
    • ジェネリック/バイオシミラーのペプチド治療薬の入手可能性
    • 医薬品開発の高コストと厳しい規制要件
    • ペプチドの生産の複雑さ

第6章 企業プロファイル

  • Novartis International AG
  • GlaxoSmithKline PLC
  • Bristol Myers Squibb Co.
  • Amgen Inc.
  • Eli Lilly and Company
  • PolyPeptide Group AG
図表

List of Figures

  • Manufacturing Process of Peptides
  • Classification of Peptides
  • Functional Classification of Therapeutic Peptides & Proteins
  • Advantages and Disadvantages of Therapeutic Peptides
  • Global Most Affected Clinical Trials by Therapy Area (2020)
  • Global Peptide Therapeutics Market by Value (2017-2021)
  • Global Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Peptide Therapeutics Market by Type (2021)
  • Global Innovative Peptide Therapeutics Market by Value (2017-2021)
  • Global Innovative Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Generic Peptide Therapeutics Market by Value (2017-2021)
  • Global Generic Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Peptide Therapeutics Market by Synthesis Technology (2021)
  • Global Solid Phase Peptide Synthesis Therapeutics Market by Value (2017-2021)
  • Global Solid Phase Peptide Synthesis Therapeutics Market Forecast by Value (2022-2026)
  • Global Liquid Phase Peptide Synthesis Therapeutics Market by Value (2017-2021)
  • Global Liquid Phase Peptide Synthesis Therapeutics Market Forecast by Value (2022-2026)
  • Global Hybrid Technology Synthesis Therapeutics Market by Value (2017-2021)
  • Global Hybrid Technology Synthesis Therapeutics Market Forecast by Value (2022-2026)
  • Global Peptide Therapeutics Market by Manufacturing Type (2021)
  • Global Outsourced Peptide Therapeutics Market Forecast by Value (2021-2026)
  • Global In-house Peptide Therapeutics Market Forecast by Value (2021-2026)
  • Global Peptide Therapeutics Market by Application (2021)
  • Global Metabolic Disorders Peptide Therapeutics Market by Value (2017-2021)
  • Global Metabolic Disorders Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Oncology Peptide Therapeutics Market by Value (2017-2021)
  • Global Oncology Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Gastrointestinal Disorders Peptide Therapeutics Market by Value (2017-2021)
  • Global Gastrointestinal Disorders Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Cardiovascular Disorders Peptide Therapeutics Market by Value (2017-2021)
  • Global Cardiovascular Disorders Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Neurological Disorders Peptide Therapeutics Market by Value (2017-2021)
  • Global Neurological Disorders Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Peptide Therapeutics Market by Region (2021)
  • North America Peptide Therapeutics Market by Value (2017-2021)
  • North America Peptide Therapeutics Market Forecast by Value (2022-2026)
  • The U.S. Peptide Therapeutics Market Forecast by Value (2021-2026)
  • The U.S. Peptide Therapeutics Market by Type (2021-2026)
  • Europe, Middle East & Africa Peptide Therapeutics Market by Value (2017-2021)
  • Europe, Middle East & Africa Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Asia Pacific Peptide Therapeutics Market by Value (2017-2021)
  • Asia Pacific Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Latin America Peptide Therapeutics Market by Value (2017-2021)
  • Latin America Peptide Therapeutics Market Forecast by Value (2022-2026)
  • Global Cancer Prevalence (2018-2023)
  • Global Healthcare Expenditure Per Capita (2017-2021)
  • Global Diabetes Prevalence (2010-2045)
  • Global Population Ages 65 Years and Above (2017-2021)
  • Number of Approved/Launched Peptide Therapeutic Drugs Worldwide (2020-2025)
  • Global GLP-1 Market Development (2018-2027)
  • Global In-House vs. Outsourced Peptide API Market Development (2020-2025)
  • Global Spending on Pharmaceutical Research and Development (2018-2026)
  • Global Biosimilar Therapeutic Peptides Market (2020-2025)

List of Tables

  • Difference between Peptides, Small Molecules & Biologics
  • Examples of Peptide-based Drugs Available in the Market
  • Source or Chemical Nature of Early Peptides
  • Synthetic Peptides in Development of COVID-19 (2020)
目次

The global peptide therapeutics market is expected to record a value of US$44.43 billion in 2026, progressing at a CAGR of 6.95%, over the period 2022-2026. The factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs. However, the market growth would be challenged by availability of generic or biosimilar peptide therapeutic drugs, high cost of developing drugs and stringent regulatory requirements and production complexity of peptides. The market is anticipated to experience certain trends like expanding volume of peptides driven by generics, rapid adoption of outsourced peptide API and rising investments in research and development of novel drugs.

The global peptide therapeutics market can be segmented on the basis of type, synthesis technology, manufacturing type and application. Based on type, the market can be bifurcated into innovative and generic. According to synthesis technology, the market can be categorized into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS) and Hybrid Technology. Whereas, on the basis of manufacturing type, the market can be divided outsourced and in-house. In terms of application, the global peptide therapeutics market can be split into chemotherapy, gastroenterology, analgesia, diabetes, pediatric & neonatology and other applications.

The fastest growing regional market is North America due to increasing research and development activities for the development of innovative peptide therapeutics and improvements in healthcare infrastructure coupled with growing prescription of peptide therapeutics on account of high presence of a large number of patients with chronic diseases such as diabetes and cancer.

Scope of the report:

  • The report provides a comprehensive analysis of the global peptide therapeutics market segmented on the basis of type, synthesis technology, manufacturing type and application region.
  • The major regional and country markets (North America, Europe, Middle East & Africa, Asia Pacific and Latin America) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The company profiles of leading players (Novartis International AG, GlaxoSmithKline PLC, Bristol Myers Squibb Co., Amgen Inc., Eli Lilly and Company and PolyPeptide Group AG) are also presented in detail.

Key Target Audience:

  • Peptide Manufacturers, Suppliers & Distributors
  • Pharmaceutical, Biopharmaceutical & Biotechnological Companies
  • Research and Development (R&D) Organizations
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Manufacturing Process of Peptides
  • 1.3. Classification of Peptides
  • 1.4. Functional Classification of Therapeutic Peptides & Proteins
  • 1.5. Examples of Peptide-based Drugs
  • 1.6. Advantages and Disadvantages of Therapeutic Peptides
  • 1.7. Source or Chemical Nature of Early Peptides

2. Impact of COVID-19

  • 2.1. Adoption of Peptides in COVID-19 Related Research
  • 2.2. Disruptions in Clinical Trials

3. Global Market Analysis

  • 3.1. Global Peptide Therapeutics Market by Value
  • 3.2. Global Peptide Therapeutics Market Forecast by Value
  • 3.3. Global Peptide Therapeutics Market by Type
    • 3.3.1. Global Innovative Peptide Therapeutics Market by Value
    • 3.3.2. Global Innovative Peptide Therapeutics Market Forecast by Value
    • 3.3.3. Global Generic Peptide Therapeutics Market by Value
    • 3.3.4. Global Generic Peptide Therapeutics Market Forecast by Value
  • 3.4. Global Peptide Therapeutics Market by Synthesis Technology
    • 3.4.1. Global Solid Phase Peptide Synthesis Therapeutics Market by Value
    • 3.4.2. Global Solid Phase Peptide Synthesis Therapeutics Market Forecast by Value
    • 3.4.3. Global Liquid Phase Peptide Synthesis Therapeutics Market by Value
    • 3.4.4. Global Liquid Phase Peptide Synthesis Therapeutics Market Forecast by Value
    • 3.4.5. Global Hybrid Technology Synthesis Therapeutics Market by Value
    • 3.4.6. Global Hybrid Technology Synthesis Therapeutics Market Forecast by Value
  • 3.5. Global Peptide Therapeutics Market by Manufacturing Type
    • 3.5.1. Global Outsourced Peptide Therapeutics Market Forecast by Value
    • 3.5.2. Global In-house Peptide Therapeutics Market Forecast by Value
  • 3.6. Global Peptide Therapeutics Market by Application
    • 3.6.1. Global Metabolic Disorders Peptide Therapeutics Market by Value
    • 3.6.2. Global Metabolic Disorders Peptide Therapeutics Market Forecast by Value
    • 3.6.3. Global Oncology Peptide Therapeutics Market by Value
    • 3.6.4. Global Oncology Peptide Therapeutics Market Forecast by Value
    • 3.6.5. Global Gastrointestinal Disorders Peptide Therapeutics Market by Value
    • 3.6.6. Global Gastrointestinal Disorders Peptide Therapeutics Market Forecast by Value
    • 3.6.7. Global Cardiovascular Disorders Peptide Therapeutics Market by Value
    • 3.6.8. Global Cardiovascular Disorders Peptide Therapeutics Market Forecast by Value
    • 3.6.9. Global Neurological Disorders Peptide Therapeutics Market by Value
    • 3.6.10. Global Neurological Disorders Peptide Therapeutics Market Forecast by Value
  • 3.7. Global Peptide Therapeutics Market by Region

4. Regional Market Analysis

  • 4.1. North America
    • 4.1.1. North America Peptide Therapeutics Market by Value
    • 4.1.2. North America Peptide Therapeutics Market Forecast by Value
    • 4.1.3. The U.S. Peptide Therapeutics Market Forecast by Value
    • 4.1.4. The U.S. Peptide Therapeutics Market Forecast by Type
  • 4.2. Europe, Middle East & Africa
    • 4.2.1. Europe, Middle East & Africa Peptide Therapeutics Market by Value
    • 4.2.2. Europe, Middle East & Africa Peptide Therapeutics Market Forecast by Value
  • 4.3. Asia Pacific
    • 4.3.1. Asia Pacific Peptide Therapeutics Market by Value
    • 4.3.2. Asia Pacific Peptide Therapeutics Market Forecast by Value
  • 4.4. Latin America
    • 4.4.1. Latin America Peptide Therapeutics Market by Value
    • 4.4.2. Latin America Peptide Therapeutics Market Forecast by Value

5. Market Dynamics

  • 5.1. Growth Drivers
    • 5.1.1. Surging Prevalence of Cancer
    • 5.1.2. Rising Healthcare Expenditure
    • 5.1.3. Growing Incidence of Metabolic Disorders
    • 5.1.4. Increasing Geriatric Population
    • 5.1.5. Accelerating Number of Approved Peptide-based Therapeutic Drugs
  • 5.2. Key Trends and Developments
    • 5.2.1. Expanding Volume of Peptides driven by Generics
    • 5.2.2. Rapid Adoption of Outsourced Peptide API
    • 5.2.3. Rising Investments in Research and Development of Novel Drugs
  • 5.3. Challenges
    • 5.3.1. Availability of Generic or Biosimilar Peptide Therapeutic Drugs
    • 5.3.2. High Cost of Developing Drugs and Stringent Regulatory Requirements
    • 5.3.3. Production Complexity of Peptides

6. Company Profiles

  • 6.1. Novartis International AG
    • 6.1.1. Business Overview
  • 6.2. GlaxoSmithKline PLC
    • 6.2.1. Business Overview
  • 6.3. Bristol Myers Squibb Co.
    • 6.3.1. Business Overview
  • 6.4. Amgen Inc.
    • 6.4.1. Business Overview
  • 6.5. Eli Lilly and Company
    • 6.5.1. Business Overview
  • 6.6. PolyPeptide Group AG
    • 6.6.1. Business Overview